1887

Abstract

The outer domain (OD) of human immunodeficiency virus (HIV)-1 gp120 represents an attractive, if difficult, target for a beneficial immune response to HIV infection. Unlike the entire gp120, the OD is structurally stable and contains the surfaces that interact with both the primary and secondary cellular receptors. The primary strain-specific neutralizing target, the V3 loop, lies within the OD, as do epitopes for two cross-reactive neutralizing monoclonal antibodies (mAbs), b12 and 2G12, and the contact sites for a number of inhibitory lectins. The OD is poorly immunogenic, at least in the context of complete gp120, but purposeful OD immunization can lead to a substantial antibody response. Here, we map the antibody generated following immunization with a clade C OD. In contrast to published data for the clade B OD, the majority of the polyclonal response to the complete clade C OD is to the V3 loop; deletion of the loop substantially reduces immunogenicity. When the loop sequence was substituted for the epitope for 2F5, a well-characterized human cross-neutralizing mAb, a polyclonal response to the epitope was generated. A panel of mAbs against the clade C OD identified two mAbs that reacted with the loop and were neutralizing for clade C but not B isolates. Other mAbs recognized both linear and conformational epitopes in the OD. We conclude that, as for complete gp120, V3 immunodominance is a property of OD immunogens, that the responses can be neutralizing and that it could be exploited for the presentation of other epitopes.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.2008/003491-0
2008-10-01
2020-01-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/10/2597.html?itemId=/content/journal/jgv/10.1099/vir.0.2008/003491-0&mimeType=html&fmt=ahah

References

  1. Alam, S. M., Scearce, R. M., Parks, R. J., Plonk, K., Plonk, S. G., Sutherland, L. L., Gorny, M. K., Zolla-Pazner, S., Vanleeuwen, S. & other authors ( 2008; ). Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 82, 115–125.[CrossRef]
    [Google Scholar]
  2. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H. & other authors ( 2000; ). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6, 200–206.[CrossRef]
    [Google Scholar]
  3. Beddows, S., Kirschner, M., Campbell-Gardener, L., Franti, M., Dey, A. K., Iyer, S. P., Maddon, P. J., Paluch, M., Master, A. & other authors ( 2006; ). Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses 22, 569–579.[CrossRef]
    [Google Scholar]
  4. Beddows, S., Franti, M., Dey, A. K., Kirschner, M., Iyer, S. P., Fisch, D. C., Ketas, T., Yuste, E., Desrosiers, R. C. & other authors ( 2007; ). A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360, 329–340.[CrossRef]
    [Google Scholar]
  5. Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S. & other authors ( 2004; ). Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78, 13232–13252.[CrossRef]
    [Google Scholar]
  6. Bures, R., Morris, L., Williamson, C., Ramjee, G., Deers, M., Fiscus, S. A., Abdool-Karim, S. & Montefiori, D. C. ( 2002; ). Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 76, 2233–2244.[CrossRef]
    [Google Scholar]
  7. Catasti, P., Fontenot, J. D., Bradbury, E. M. & Gupta, G. ( 1995; ). Local and global structural properties of the HIV-MN V3 loop. J Biol Chem 270, 2224–2232.[CrossRef]
    [Google Scholar]
  8. Catasti, P., Bradbury, E. M. & Gupta, G. ( 1996; ). Structure and polymorphism of HIV-1 third variable loops. J Biol Chem 271, 8236–8242.[CrossRef]
    [Google Scholar]
  9. Chen, B., Vogan, E. M., Gong, H., Skehel, J. J., Wiley, D. C. & Harrison, S. C. ( 2005; ). Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433, 834–841.[CrossRef]
    [Google Scholar]
  10. Chen, H., Xu, X. & Jones, I. M. ( 2007; ). Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology 4, 33 [CrossRef]
    [Google Scholar]
  11. Fenouillet, E., Barbouche, R. & Jones, I. M. ( 2007; ). Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. Antioxid Redox Signal 9, 1009–1034.[CrossRef]
    [Google Scholar]
  12. Gauduin, M. C., Parren, P. W., Weir, R., Barbas, C. F., Burton, D. R. & Koup, R. A. ( 1997; ). Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 3, 1389–1393.[CrossRef]
    [Google Scholar]
  13. Hartley, O., Klasse, P. J., Sattentau, Q. J. & Moore, J. P. ( 2005; ). V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 21, 171–189.[CrossRef]
    [Google Scholar]
  14. Iyer, S. P., Franti, M., Krauchuk, A. A., Fisch, D. N., Ouattara, A. A., Roux, K. H., Krawiec, L., Dey, A. K., Beddows, S. & other authors ( 2007; ). Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers. AIDS Res Hum Retroviruses 23, 817–828.[CrossRef]
    [Google Scholar]
  15. Karlsson Hedestam, G. B., Fouchier, R. A., Phogat, S., Burton, D. R., Sodroski, J. & Wyatt, R. T. ( 2008; ). The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6, 143–155.[CrossRef]
    [Google Scholar]
  16. Kitabwalla, M., Ferrantelli, F., Wang, T., Chalmers, A., Katinger, H., Stiegler, G., Cavacini, L. A., Chou, T. C. & Ruprecht, R. M. ( 2003; ). Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses 19, 125–131.[CrossRef]
    [Google Scholar]
  17. Korber, B. T. M., Brander, C., Haynes, B. F., Koup, R., Moore, J. P., Walker, B. D. & Watkins, D. I. ( 2007; ). HIV Molecular Immunology 2006/2007. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory.
  18. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. ( 1998; ). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648–659.[CrossRef]
    [Google Scholar]
  19. Li, Y., Cleveland, B., Klots, I., Travis, B., Richardson, B. A., Anderson, D., Montefiori, D., Polacino, P. & Hu, S. L. ( 2008; ). Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82, 638–651.[CrossRef]
    [Google Scholar]
  20. Mascola, J. R., D'Souza, P., Gilbert, P., Hahn, B. H., Haigwood, N. L., Morris, L., Petropoulos, C. J., Polonis, V. R., Sarzotti, M. & Montefiori, D. C. ( 2005; ). Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79, 10103–10107.[CrossRef]
    [Google Scholar]
  21. Montefiori, D. C. ( 2004; ). Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. In Current Protocols in Immunology, pp. 12.11.1–12.11.15. Edited by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober & R. Coico. Hoboken, NJ: Wiley.
  22. Moore, P. L., Crooks, E. T., Porter, L., Zhu, P., Cayanan, C. S., Grise, H., Corcoran, P., Zwick, M. B., Franti, M. & other authors ( 2006; ). Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80, 2515–2528.[CrossRef]
    [Google Scholar]
  23. Muster, T., Guinea, R., Trkola, A., Purtscher, M., Klima, A., Steindl, F., Palese, P. & Katinger, H. ( 1994; ). Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68, 4031–4034.
    [Google Scholar]
  24. Pantophlet, R. & Burton, D. R. ( 2006; ). GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24, 739–769.[CrossRef]
    [Google Scholar]
  25. Pantophlet, R., Aguilar-Sino, R. O., Wrin, T., Cavacini, L. A. & Burton, D. R. ( 2007; ). Analysis of the neutralization breadth of the anti-V3 antibody F425–B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364, 441–453.[CrossRef]
    [Google Scholar]
  26. Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W. & Choopanya, K. ( 2006; ). Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194, 1661–1671.[CrossRef]
    [Google Scholar]
  27. Rodenburg, C. M., Li, Y., Trask, S. A., Chen, Y., Decker, J., Robertson, D. L., Kalish, M. L., Shaw, G. M., Allen, S. & other authors ( 2001; ). Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 17, 161–168.[CrossRef]
    [Google Scholar]
  28. Roux, K. H., Zhu, P., Seavy, M., Katinger, H., Kunert, R. & Seamon, V. ( 2004; ). Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol Immunol 41, 1001–1011.[CrossRef]
    [Google Scholar]
  29. Russell, N. D., Graham, B. S., Keefer, M. C., McElrath, M. J., Self, S. G., Weinhold, K. J., Montefiori, D. C., Ferrari, G., Horton, H. & other authors ( 2007; ). Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 44, 203–212.[CrossRef]
    [Google Scholar]
  30. Schulke, N., Vesanen, M. S., Sanders, R. W., Zhu, P., Lu, M., Anselma, D. J., Villa, A. R., Parren, P. W., Binley, J. M. & other authors ( 2002; ). Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 76, 7760–7776.[CrossRef]
    [Google Scholar]
  31. Su, L., Graf, M., Zhang, Y., von Briesen, H., Xing, H., Kostler, J., Melzl, H., Wolf, H., Shao, Y. & Wagner, R. ( 2000; ). Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B′) recombinant strain in China. J Virol 74, 11367–11376.[CrossRef]
    [Google Scholar]
  32. Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P. & Katinger, H. ( 1996; ). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70, 1100–1108.
    [Google Scholar]
  33. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M. & Kappes, J. C. ( 2002; ). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46, 1896–1905.[CrossRef]
    [Google Scholar]
  34. Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M. & other authors ( 2003; ). Antibody neutralization and escape by HIV-1. Nature 422, 307–312.[CrossRef]
    [Google Scholar]
  35. Yang, X., Tomov, V., Kurteva, S., Wang, L., Ren, X., Gorny, M. K., Zolla-Pazner, S. & Sodroski, J. ( 2004; ). Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J Virol 78, 12975–12986.[CrossRef]
    [Google Scholar]
  36. Yao, Y. X., Ren, J., Heinen, P., Zambon, M. & Jones, I. M. ( 2004; ). Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein. J Infect Dis 190, 91–98.[CrossRef]
    [Google Scholar]
  37. Yuan, W., Bazick, J. & Sodroski, J. ( 2006; ). Characterization of the multiple conformational states of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J Virol 80, 6725–6737.[CrossRef]
    [Google Scholar]
  38. Zhao, Y., Chapman, D. A. & Jones, I. M. ( 2003; ). Improving baculovirus recombination. Nucleic Acids Res 31, E6–E6.[CrossRef]
    [Google Scholar]
  39. Zhou, T., Xu, L., Dey, B., Hessell, A. J., Van Ryk, D., Xiang, S. H., Yang, X., Zhang, M. Y., Zwick, M. B. & other authors ( 2007; ). Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732–737.[CrossRef]
    [Google Scholar]
  40. Zolla-Pazner, S. ( 2005; ). Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14, 69–72.
    [Google Scholar]
  41. Zolla-Pazner, S., Gomy, M. K. & Nyambi, P. N. ( 1999; ). The implications of antigenic diversity for vaccine development. Immunol Lett 66, 159–164.[CrossRef]
    [Google Scholar]
  42. Zolla-Pazner, S., Cohen, S. S., Krachmarov, C., Wang, S., Pinter, A. & Lu, S. ( 2008; ). Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372, 233–246.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.2008/003491-0
Loading
/content/journal/jgv/10.1099/vir.0.2008/003491-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error